Date: 2015-09-03
Type of information: Nomination
Compound:
Company: Genenta Science (Italy)
Therapeutic area: Cancer - Oncology - Rare diseases
Type agreement: nomination
Action mechanism: gene therapy
Disease:
Details: * On September 3, 2015, Genenta Science, a biotech company focused on hematopoietic stem cell gene therapy,
announced that Tiziana Mattioni, Ph.D. is joining the company as its Chief Operating Officer. Dr. Mattioni comes to Genenta Science from Merck Serono, a division in Merck KGaA – Germany, where she most recently served as Director Global Program Leader in Oncology. At Merck Serono, dr. Mattioni led the development of Cancer Vaccines and Anti-angiogenic drugs. Prior to her position as a leader in oncology, dr. Mattioni held roles of increasing responsibility in Clinical Trial Operations and Medical Safety (pharmacovigilance).
Dr. Mattioni earned her doctorate degree in microbiology from Genoa University and in cellular biology from Geneva
University and also holds a Postdoctoral fellowship at the Dana-Farber Cancer Center, Boston, USA, Sloan-Kettering
Cancer Center, NY, USA and at the University of Geneva, Switzerland.
Financial terms:
Latest news:
